DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
BCBS is a federation — coverage rules vary by state plan (BCBS of Texas ≠ Anthem BCBS California). Most commercial plans cover GLP-1s with prior auth. State plan variance is the biggest hurdle.
Blue Cross Blue Shield requires the following before approving Wegovy:
Top denial patterns we see in 2026 based on appeal-claim data:
Check your specific state plan formulary first — BCBS Federal Employee Program (FEP) covers Wegovy with looser PA than state plans. Anthem BCBS states differ from independent BCBS state plans.
State plan Member Services → Pharmacy Appeal → typically 30-day decision window.
Wegovy (semaglutide 2.4mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Blue Cross Blue Shield formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.